Thursday, 27 January 2022
New research has shown that over-activity in a specific area of the brain is linked to certain symptoms of Schizophrenia, opening up possibilities for the development of more targeted treatments.
Researchers from the 糖心原创 found that faulty inhibitory neurotransmission and abnormally increased activity in the hippocampus doesn’t disrupt the ability to filter out irrelevant information, a key process which has been shown to be deficient in patients with schizophrenia and is thought to cause hallucinations or delusions but does disrupt associative learning. Deficits in associative learning, such as Pavlovian fear conditioning, have been linked to the negative symptoms of the disorder which include reduced motivation and disrupted emotional and reward processing. Their findings have been published in
Schizophrenia is a major illness. At any one time about 220,000 people are being treated for schizophrenia in the UK by the NHS. It is psychotic illness which exhibits itself in three ways: negative symptoms such as lethargy, apathy and social withdrawal, positive symptoms such as hallucinations and delusions and cognitive symptoms such as impaired memory. Either or all three may be present in an individual at the same time.
Neurons in the brain interact by sending each other chemical messages, so-called neurotransmitters. Gamma-aminobutyric acid (GABA) is the most common inhibitory neurotransmitter, which is important to restrain neural activity, preventing neurons from getting too trigger-happy and from firing too much or responding to irrelevant stimuli.
The hippocampus is a part of the brain that sits within our temporal lobes and plays a major role in our memories and emotions. This latest research has implications for understanding more about how this part of the brain affects specific aspects of schizophrenia.
The study was carried led by post-doctoral researcher Stuart Williams, he said: “We know that people with schizophrenia have increased hippocampal activity, we wanted to explore this further and find out exactly how this manifests itself. Through our research carried out in rats we were able to ascertain the importance of GABAergic inhibition within the hippocampus in relation to certain symptoms associated with schizophrenia. Specifically, we found no evidence that faulty inhibition within the hippocampus disrupts behaviours related to the underlying cognitive processes which are thought to contribute to the onset of hallucinations or delusions but did find that it may contribute to some of the negative symptoms, disrupting associative learning in the form of conditioned fear.”
This study has important implications for developing treatments for the negative symptoms of schizophrenia.
Stuart continues: “By revealing previously unknown detail about the role of aberrant activity in the hippocampus, we are providing insights into the behavioural consequences that disruption of specific neural structures, such as the hippocampus, have in schizophrenia. This could help to develop more targeted treatments that improve the management of specific aspects of schizophrenia symptomatology such as improving negative symptoms, potentially by dampening down this over-activity in the hippocampus."
Story credits
More information is available from Dr Tobias Bast on Tobias.bast@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.